Investment Firm Builds Position in TERN Stock, According to Recent SEC FilingThe Motley Fool • 03/05/26
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC FilingThe Motley Fool • 02/20/26
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock SurgeThe Motley Fool • 02/17/26
Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High?Zacks Investment Research • 02/04/26
Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/07/26
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/11/25
Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia TranscriptSeeking Alpha • 12/09/25
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual MeetingGlobeNewsWire • 12/08/25
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for InvestorsThe Motley Fool • 12/03/25
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in LondonGlobeNewsWire • 11/14/25
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/10/25
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst UpgradesBenzinga • 11/03/25
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual MeetingGlobeNewsWire • 11/03/25
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in ObesityGlobeNewsWire • 10/21/25